About PAMORAs

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).¹*

MOVENTIG may be used with or without laxatives.¹

Adverse Events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for Prescribing Information.

PAMORAs as a treatment option for OIC

Opioid antagonist drugs can be helpful in relieving the symptoms of OIC, however drugs such as naloxone cross the blood-brain barrier and so can compromise pain control. Opioid antagonist drugs that primarily block opioid receptors in the gastrointestinal (GI) tract can relieve the symptoms of OIC without diminishing pain control. This class of drugs is known as peripherally acting mu-opioid receptor antagonists (PAMORAs).²

Watch the video below to hear from expert speakers on PAMORAs as a treatment option for OIC.

*Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.¹

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

How useful was this page to you?

Average:

References

1. MOVENTIG Summary of Product Characteristics.

2. Farmer AD, et al. UEG Journal. 2019;7(1):7–20.

M-N/A-HQ-11-23-0065 March 2024

Europe

About PAMORAs

PAMORAs as a treatment option for OIC